Safety

Actor Portrayal

Well-tolerated across
clinical trials1

Most Common AE1

2%
Incidence of nausea:
2% Nurtec ODT vs 0.4% placebo

Safety assessment included 682 patients who received a single dose of rimegepant ODT 75 mg and 693 patients who received placebo during the double-blind treatment.1,2


Long-term safety maintained through 52 weeks1

2.7% (n=48/1800) of patients receiving rimegepant discontinued due to AEs3

1798 subjects were exposed to >111,000 doses of rimegepant4

Can be used to treat up to 15 migraines per month1

A long-term open-label safety study evaluated rimegepant 75 mg in patients (N=1800) exposed to multiple doses, as needed up to one dose per day, for up to 52 weeks.1,3

References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. 3. Croop R, Berman G, Kudrow D, et al. Long-term safety of rimegepant 75 mg for the acute treatment of migraine (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 4. Data on File. RIM113. Biohaven Pharmaceuticals Inc.